FrancophonIA/ELRC3.0 huggingface dataset:
English: It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytrypamine (also called serotonin) and dopamine.
Estonian: Arvatakse, et olansapiini kasulik toime seisneb neurotransmitterite 5-hüdroksütrüptamiini (serotoniin) ja dopamiini retseptorite blokeerimises.
English: It can also be used to prevent the recurrence (when symptoms come back) of these episodes in adults with bipolar disorder (a mental illness with alternating periods of high mood and depression) who have responded to an initial course of treatment.
Estonian: Seda võib kasutada ka episoodide kordumise (sümptomite taastekkimise) ennetamiseks bipolaarse meeleoluhäirega (vaimuhaigus, kus vahelduvad meeleolu liigne tõus ja langus) täiskasvanud patsientidel, kellel on tekkinud esialgne ravivastus.
English: Its exact mechanism of action is unknown, but it attaches to several receptors on the surface of nerve cells in the brain.
Estonian: Olansapiini täpne toimemehhanism ei ole teada, kuid aine seondub aju närvirakkude pinnal mitme retseptoriga.
English: The Committee recommended that Olanzapine Mylan be given marketing authorisation.
Estonian: Komitee soovitas anda Olanzapine Mylanile müügiloa.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) OLANZAPINE MYLAN EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE OLANZAPINE MYLAN Kokkuvõte üldsusele
English: Because Olanzapine Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Estonian: Et Olanzapine Mylan on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Because Olanzapine Mylan is a generic medicine, studies have been limited to tests to demonstrate that it is bioequivalent to the reference medicine (i.e. that the two medicines produce the same levels of the active substance in the body).
Estonian: Kuna Olanzapine Mylan on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Olanzapine Mylani bioekvivalentsust võrdlusravimiga (st need ravimid tekitavad organismis toimeainet samal määral).
English: Olanzapine Mylan is used to treat adults with schizophrenia.
Estonian: Olanzapine Mylani kasutatakse täiskasvanud patsientidel skisofreenia ravimiseks.
English: This means that Olanzapine Mylan is similar to a ‘reference medicine' already authorised in the European Union (EU) called Zyprexa.
Estonian: See tähendab, et Olanzapine Mylan on sarnane võrdlusravimiga Zyprexa, millel juba on Euroopa Liidus müügiluba.
English: This disrupts signals transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other.
Estonian: See häirib neurotransmitterite (keemilised ained, mille abil toimub närvirakkudevaheline signaalivahetus) vahendatavaid närviimpulsse.
English: Olanzapine Mylan is also effective in maintaining improvement in patients who have responded to an initial course of treatment.
Estonian: Olanzapine Mylani saab kasutada ka esialgse ravivastusega patsientide paranemistulemuse efektiivseks säilitamiseks.
English: Olanzapine Mylan is a medicine containing the active substance olanzapine.
Estonian: Olanzapine Mylan on ravim, mis sisaldab toimeainena olansapiini.
English: Other information about Olanzapine Mylan:
Estonian: Muu teave Olanzapine Mylani kohta
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Olanzapine Mylan has been shown to have comparable quality and to be bioequivalent to Zyprexa.
Estonian: Inimravimite komitee otsustas, et Olanzapine Mylani võrdväärne kvaliteet ja bioekvivalentsus ravimiga Zyprexa on vastavalt Euroopa Liidu nõuetele tõendatud.
English: Olanzapine Mylan is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Estonian: Samuti kasutatakse Olanzapine Mylani täiskasvanute mõõdukate või raskete maaniaepisoodide (meeleolu äärmuslik tõus) raviks.
English: The full EPAR for Olanzapine Mylan can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Olanzapine Mylani kohta leiate siit.
English: Olanzapine Mylan is a ‘generic medicine'.
Estonian: Olanzapine Mylan on geneeriline ravim.
English: Why has Olanzapine Mylan been approved?
Estonian: Miks Olanzapine Mylan heaks kiideti?
English: The active substance in Olanzapine Mylan, olanzapine, is an antipsychotic medicine.
Estonian: Olanzapine Mylani toimeaine olansapiin on antipsühhootikum.
English: What is the risk associated with Olanzapine Mylan?
Estonian: Mis riskid kaasnevad Olanzipine Mylaniga?
English: What is Olanzapine Mylan?
Estonian: Mis on Olanzapine Mylan?
English: How is Olanzapine Mylan used?
Estonian: Kuidas Olanzapine Mylani kasutatakse?
English: What is Olanzapine Mylan used for?
Estonian: Milleks Olanzapine Mylani kasutatakse?
English: How does Olanzapine Mylan work?
Estonian: Kuidas Olanzapine Mylan toimib?
English: How has Olanzapine Mylan been studied?
Estonian: Kuidas Olanzapine Mylani uuriti?
English: It is available as tablets (15, 30 and 45 mg).
Estonian: Seda turustatakse tablettidena (15, 30 või 45 mg).
English: The tablets should be swallowed with water.
Estonian: Tabletid tuleb alla neelata koos veega.
English: The full EPAR for Paglitaz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Paglitazi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Paglitaz on 21 March 2012.
Estonian: Euroopa Komisjon andis Paglitazi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. märtsil
English: The recommended starting dose of Paglitaz is 15 or 30 mg once a day.
Estonian: Paglitazi soovitatav algannus on 15 või 30 mg üks kord ööpäevas.
English: Treatment with Paglitaz should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Estonian: Paglitazi ravivastus tuleb kolme kuni kuue kuu möödudes läbi vaadata ning lõpetada ravi patsientidel, kes ei saa ravist piisavalt kasu.
English: Other information about Paglitaz
Estonian: Muu teave Paglitazi kohta
English: The active substance in Paglitaz, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Estonian: Paglitazi toimeaine pioglitasoon suurendab rakkude (rasva-, lihas- ja maksarakud) tundlikkust insuliini suhtes, mis tähendab, et organism kasutab enda toodetavat insuliini paremini ära.
English: For more information about treatment with Paglitaz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Paglitaziga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Paglitaz.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Paglitaz is a ‘generic medicine'.
Estonian: Paglitaz on geneeriline ravim.
English: Because Paglitaz is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Paglitaz on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Therefore, the CHMP's view was that, as for Actos, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Actose korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
English: This means that Paglitaz is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos.
Estonian: See tähendab, et Paglitaz on sarnane võrdlusravimiga Actos, millel juba on Euroopa Liidus müügiluba.
English: Because Paglitaz is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos.
Estonian: Et Paglitaz on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Paglitazi bioekvivalentsust võrdlusravimiga Actos.
English: Paglitaz is a medicine that contains the active substance pioglitazone.
Estonian: Paglitaz on ravim, mis sisaldab toimeainena pioglitasooni.
English: Paglitaz is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Estonian: Paglitazi kasutatakse eelkõige ülekaaluliste täiskasvanud (vähemalt 18-aastaste) patsientide II tüüpi diabeedi (suhkurtõve) raviks.
English: The CHMP concluded that, in accordance with EU requirements, Paglitaz has been shown to have comparable quality and to be bioequivalent to Actos.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Paglitaz võrdväärne kvaliteet ja bioekvivalentsus ravimiga Actos.
English: Paglitaz can also be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Estonian: Paglitazi tohib kasutada ka koos insuliiniga patsientidel, kellele üksnes insuliini manustamine ei mõju rahuldavalt ja kes ei saa kasutada metformiini.
English: The Committee recommended that Paglitaz be given marketing authorisation.
Estonian: Komitee soovitas anda ravimi müügiloa.
English: Why has Paglitaz been approved?
Estonian: Miks Paglitaz heaks kiideti?
English: Paglitaz should not be used in patients on dialysis (a blood clearance technique used in people with kidney disease).
Estonian: Paglitazi ei tohi kasutada patsiendid, kes saavad dialüüsi (teatud verepuhastustehnika neeruhaiguste korral).
English: This is a summary of the European public assessment report (EPAR) for Paglitaz.
Estonian: Käesolev dokument on ravimi Paglitaz Euroopa avaliku hindamisaruande kokkuvõte.
English: What are the benefits and risks of Paglitaz?
Estonian: Milles seisneb Paglitazi kasulikkus ja mis riskid ravimiga kaasnevad?
English: How is Paglitaz used?
Estonian: Kuidas Paglitazi kasutatakse?
English: What is Paglitaz used for?
Estonian: Milleks Paglitazi kasutatakse?
English: What is Paglitaz?
Estonian: Mis on Paglitaz?
English: Paglitaz can also be used in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of antidiabetes medicine) when metformin is not suitable (‘dual therapy').
Estonian: Paglitazi tohib kasutada ka koos metformiiniga patsientidel, kelle haigus ainult metformiini kasutamisel rahuldavalt ravile ei allu, või koos sulfonüüluurearavimiga (samuti diabeediravim), kui metformiini ei saa kasutada (ravi kahe preparaadiga).
English: Paglitaz is used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable.
Estonian: Paglitazi kasutatakse ainsa ravimina patsientidel, kellele ei sobi metformiin (samuti diabeediravim).
English: Paglitaz can also be used together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite dual therapy by mouth (‘triple therapy').
Estonian: Paglitazi tohib kasutada koos metformiini ja sulfonüüluurearavimiga patsientidel, kelle haigus ei allu piisavalt suukaudsele ravile kahe preparaadiga (ravi kolme preparaadiga).
English: How has Paglitaz been studied?
Estonian: Kuidas Paglitazi uuriti?
English: How does Paglitaz work?
Estonian: Kuidas Paglitaz toimib?
English: ● OTHER CONDITIONS
Estonian: ● MUUD TINGIMUSED
English: A course of treatment usually lasts for 8 weeks.
Estonian: Ravikuur kestab tavaliselt 8 nädalat.
English: This first three months, is the most critical period post-transplantation.
Estonian: Esimesed kolm kuud on kõige kriitilisem transplantatsioonijärgne periood.
English: The clinical relevance is unknown.
Estonian: Selle kliiniline tähtsus on teadmata.
English: The expiry date refers to the last day of that month..
Estonian: Kõlblikkusaeg viitab kuu viimasele päevale.
English: Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http://www.emea.eu.int/
Estonian: Täpne informatsioon selle ravimi kohta on kättesaadav Euroopa Ravimiameti (EMEA) kodulehel http://www.emea.eu.int/
English: Date of renewal: 14 April 2004
Estonian: Müügiloa uuendamise kuupäev: 14. aprill 2004
English: This is extremely important because using more than one medicine at the same time may strengthen or weaken the effect of the medicines you are taking.
Estonian: See on äärmiselt tähtis, kuna rohkem kui ühe ravimi samaaegne kasutamine võib suurendada või vähendada kasutatavate ravimite toimet.
English: This is attributable to the humanisation of the protein.
Estonian: See on seotud proteiini humaniseerimisega.
English: Please read the section below on breast-feeding.
Estonian: Palun lugege lõiku imetamise kohta allpool.
English: These side effects can be serious and you may need urgent medical attention.
Estonian: Need kõrvaltoimed võivad olla tõsised ja vajada kohest arstiabi.
English: Like all medicines, Zenapax can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka Zenapax põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 26 February 1999
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 26. veebruar 1999
English: Other drug/substances should not be added or infused simultaneously through the same intravenous line.
Estonian: Teisi ravimeid/aineid ei tohi infusioonikotti lisada või manustada samaaegselt sama veenitee kaudu.
English: You may receive subsequent infusions within a day before or after the scheduled administration.
Estonian: Järgnevad infusioonid võite saada päev varem või hiljem enne ettenähtud manustamisaega.
English: Placebo n=293
Estonian: Platseebo n=293
English: - Do not freeze.
Estonian: - Mitte hoida sügavkülmas.
English: D-79639 Grenzach-Wyhlen GERMANY
Estonian: D-79639 Grenzach-Wyhlen Saksamaa
English: From a microbiological point of view, however, the diluted product should be used immediately.
Estonian: Mikrobioloogilisest seisukohast tuleks lahjendatud ravim manustada koheselt.
English: However, the data show considerable inter-animal variation and were within the historical control range for this species.
Estonian: Samas näitavad andmed märkimisväärset loomadevahelist varieeruvust, jäädes selle liigi puhul aja jooksul täheldatud kontrollvahemiku piiridesse.
English: Zenapax should not be used in pregnant women unless it is clearly necessary.
Estonian: Zenapax'i ei tohi kasutada raseduse ajal, kui see ei ole hädavajalik.
English: Instructions for the preparation of Zenapax infusions are described in section 6.6.
Estonian: Juhised Zenapax infusioonilahuse valmistamiseks on toodud lõigus 6.6.
English: In the event that you do develop an allergic reaction, your doctor will treat you with appropriate medication.
Estonian: Kui teil peaks tekkima allergiline reaktsioon, määrab arst selle raviks sobiva ravimi.
English: Monoclonal antibodies are proteins which recognise and bind to other unique proteins in the body called antigens.
Estonian: Monoklonaalsed antikehad on valgud, mis tunnevad ära ja seonduvad organismis teiste ainulaadsete valkudega, mida nimetatakse antigeenideks.
English: The data from the four studies (O14392, O14393, O14874 and O15301) showed that the incidence and types of adverse events were similar in both placebo-treated and Zenapax-treated patients.
Estonian: Andmed neljast uuringust (O14392, O14393, O14874 ja O15301) näitasid, et kõrvalnähtude esinemissagedus ja tüüp olid platseebo-grupis ja Zenapax-ravi saanud patsientidel sarnased.
English: Care must be taken to assure sterility of prepared solution, since the drug product does not contain any antimicrobial preservative or bacteriostatic agents.
Estonian: Lahuse valmistamisel tuleb tagada steriilsus, kuna ravim ei sisalda mingeid antimikroobseid säilitusaineid ega bakteriostaatilisi aineid.
English: You should not use this medicine if you are pregnant unless your doctor decides that it is necessary for you.
Estonian: Raseduse ajal tohib seda ravimit kasutada ainult juhul, kui teie arst otsustab, et see on teile vajalik.
English: Most of these high values occurred either on the first day post-transplant when patients received high doses of corticosteroids or in patients with diabetes.
Estonian: Enamus nendest juhtudest ilmnes esimesel siirdamisjärgsel päeval, kui patsiendid said kortikosteroidide suuri annuseid või diabeediga patsientidel.
English: Experience with Zenapax in elderly patients (older than 65 years) is limited because of the small number of older patients who undergo renal transplantation, but there is no evidence that elderly patients require a different dosage from younger patients.
Estonian: Zenapax´i kasutamise kogemus eakatel (üle 65 aastastel) patsientidel on vähene, kuna eakatele isikutele tehakse harva neerutransplantatsiooni, kuid samas puuduvad tõendid, et eakatel patsientidel oleks nõutav noorematest patsientidest erinev annustamine.
English: Pharmacotherapeutic group: selective immunosuppressive agents ATC code: L04A A08
Estonian: Farmakoterapeutiline grupp: selektiivsed immuunsupressiivsed ained ATC-kood: L04AA08
English: - if you are breast-feeding.
Estonian: - kui te toidate last rinnaga.
English: Within the system organ classes, undesirable effects are listed under headings of frequency, using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Estonian: Organsüsteemi klassides on kõrvaltoimed loetletud esinemissageduse järgi, kasutades järgmisi kategooriaid: väga sage (≥1/10); sage (≥1/100...<1/10); aeg-ajalt (≥1/1000...<1/100); harv (≥1/10000...<1/1000); väga harv (<1/10000), teadmata (ei saa hinnata olemasolevate andmete põhjal).
English: Therapy with medicines which help to suppress the body's natural defence mechanisms can increase the risk for developing malignancies or infections.
Estonian: Ravi preparaatidega, mis aitavad maha suruda organismi loomulikke kaitsemehhanisme, võib suurendada pahaloomuliste kasvajate või infektsioonide tekke ohtu.
English: The product is not intended to be stored after dilution unless the dilution has taken place under controlled and validated aseptic conditions.
Estonian: Pärast lahjendamist ei tohi ravimit säilitada, välja arvatud juhul, kui lahjendamisprotseduur toimus kontrollitud ja valideeritud aseptilistes tingimustes.
English: 5 ml in a vial (Type I glass).
Estonian: 5 ml viaalis (I tüüpi klaas).
English: Pruritus Night sweats Hyperhidrosis
Estonian: Öine higistamine Hüperhidroos
English: The first dose is given within 24 hours before your transplant.
Estonian: Esimene annus manustatakse 24 tunni jooksul enne siirdamist.
English: There was no cross reactivity in-vitro between daclizumab and human cryosections (28 organs) at concentrations up to 56 mg/ml, demonstrating the absence of non-specific binding.
Estonian: In vitro ei esinenud ristuvat reaktiivsust daklitsumabi ja inimese krüolõikude (28 organit) vahel kontsentratsioonides kuni 56 mg/ml, mis näitab mittespetsiifilise seondumise puudumist.
English: Pregnancy and breast-feeding You must not use this medicine if you are breast-feeding.
Estonian: Rasedus ja imetamine Rinnaga toitmise ajal ei tohi seda ravimit kasutada.
English: Adverse events occurring with a frequency of ≥2% in patients in either group during the first 3 months post-transplant are listed below.
Estonian: Järgnevalt on loetletud kõrvaltoimed, mida esines kummagi grupi patsientidel esimese 3 transplantatsioonijärgse kuu jooksul esinemissagedusega ≥2%.
English: Post-traumatic pain
Estonian: Posttraumaatiline valu
English: Zenapax may cause damage to your unborn or breast-feeding baby.
Estonian: Zenapax'il võib olla kahjulik toime veel sündimata või rinnapiimatoidul lapsele.
English: Chemical and physical in-use stability has been demonstrated for 24 hours at 2 °C - 8 °C or for 4 hours at 25 °C.
Estonian: Füüsikaline ja keemiline stabiilsus püsib lahjendatult 24 tundi temperatuuril 2°C...8°C või 4 tundi temperatuuril 25°C.
English: THE MARKETING AUTHORISATION HOLDER Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Estonian: Piiratud tingimustel väljastatav retseptiravim (vt lisa I: Ravimi omaduste kokkuvõte, lõik 4.2)
English: Common side effects (occurring in between 1 and 10 patients out of 100) are inflammation of the throat (pharyngitis); runny nose (rhinitis); diabetes mellitus; high blood sugar (hyperglycaemia); fluid overload; dehydration; anxiety; depression; dizziness; sensation of pins and needles; blurred vision; fast heart rate (tachycardia); bleeding (haemorrhage); blood clot (thrombosis); low blood pressure (hypotension); accumulation of lymph fluid in one part of the body (lymphocele); severe shortness of breath, including when laying flat at night (pulmonary oedema); fluid on the lungs (pleural effusion); collapsed lung (atelectasis); lack of oxygen in the body (hypoxia); congestion; cough; noisy or abnormal breath sounds, including crackling breath sounds (rales); bloated stomach; stomach pain or discomfort; flatulence; haemorrhoids; rash; itchy skin; acne; night sweats; increased sweating; excessive hair growth (hirsutism); back pain; muscle cramps, particularly in the legs; pain in the joints (arthralgia); pain in the muscles (myalgia); chest pain; pain in general; tiredness; skin irritation at the site of injection; fever; chills; general weakness; pain in the loins and changes or difficulty in passing urine (hydronephrosis); blood in the urine; pain on passing urine (dysuria); reduced urine output (oliguria); pain following surgery.
Estonian: Sageli esinevad kõrvaltoimed (ühel kuni kümnel patsiendil 100-st) on neelupõletik (farüngiit); nohu (riniit); suhkurtõbi; kõrge veresuhkru tase (hüperglükeemia); vedeliku ülekoormus; veetustumine; ärevus; depressioon; pearinglus; surisemistunne; ähmane nägemine; kiire südametegevus (tahhükardia); verejooks (hemorraagia); verehüüve (tromboos); madal vererõhk (hüpotensioon); lümfivedeliku kogunemine ühes kehaosas (lümfotseele); tugev õhupuudus, sealhulgas öösel pikali lamades (kopsuturse); vedelik kopsukelmeõõnes (pleura efusioon); kopsu kokkulangemine (atelektaas); organismi hapnikupuudus (hüpoksia); tungliigveresus (kongestioon); köha; vali või ebanormaalne hingamiskahin, sealhulgas räginad; pingetunne kõhus; kõhuvalu või ebamugavustunne kõhus; kõhupuhitus; hemorroidid; lööve; naha sügelus; akne; öine higistamine; suurenenud higistamine; liigne karvakasv (hirsutism); seljavalu; lihaskrambid, eriti jalgades; liigesvalu (artralgia); lihasvalu (müalgia); valu rinnus; valu üldiselt; väsimus; nahaärritus süstekohas; palavik; külmavärinad; üldine nõrkus; nimmevalu ning muutunud või raskendatud urineerimine (hüdronefroos); vere leid uriinis; valulik urineerimine (düsuuria); vähenenud uriinieritus (oliguuria); operatsioonijärgne valu.
English: These side effects may occur when using Zenapax.
Estonian: Need kõrvaltoimed võivad tekkida Zenapax'i kasutamise ajal.